Table of Contents

CSF1R-Mediated Myeloid Cell Depletion Prolongs Lifespan But Aggravates Distinct Motor Symptoms in a Model of Multiple System Atrophy

  1. Alana Hoffmann1
  1. 1Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054, Germany
  2. 2Department of Neurosciences, University of California-San Diego, La Jolla, California 92093
  3. 3Department of Cellular and Molecular Medicine, University of California-San Diego, La Jolla, California 92093
  4. 4Division of Neuroscience, National Institute on Aging, National Institutes of Health, Bethesda, Maryland 20892
  5. 5Center of Rare Diseases Erlangen (ZSEER), University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054, Germany
  1. Author contributions: K.B., J.B.F., M.M., A.L., I.N., C. Gauer, V.L., S.J.M., I.C., B.F., H.Y.K., J.C.M.S., R.A.R., J.W., and A.H. performed research; K.B., I.N., C. Gauer, V.L., S.J.M., H.Y.K., C.K. Glass, J.C.M.S., R.A.R., J.W., and A.H. analyzed data; K.B., J.C.M.S., and A.H. wrote the first draft of the paper; K.B., J.B.F., A.L., I.N., C. Gauer, V.L., S.J.M., I.C., B.F., H.Y.K., E.M., C.K. Glass, J.C.M.S., R.A.R., J.W., and A.H. edited the paper; K.B., J.C.M.S., and A.H. wrote the paper; I.C., B.F., H.Y.K., E.M., C.K. Glass, J.C.M.S., and R.A.R. contributed unpublished reagents/analytic tools; J.C.M.S., J.W., and A.H. designed research.

  • A. Hoffmann's present address: United Kingdom Dementia Research Institute at The University of Edinburgh, Centre for Discovery Brain Sciences, Chancellor's Building, University of Edinburgh, United Kingdom.

Abstract

As the CNS-resident macrophages and member of the myeloid lineage, microglia fulfill manifold functions important for brain development and homeostasis. In the context of neurodegenerative diseases, they have been implicated in degenerative and regenerative processes. The discovery of distinct activation patterns, including increased phagocytosis, indicated a damaging role of myeloid cells in multiple system atrophy (MSA), a devastating, rapidly progressing atypical parkinsonian disorder. Here, we analyzed the gene expression profile of microglia in a mouse model of MSA (MBP29-hα-syn) and identified a disease-associated expression profile and upregulation of the colony-stimulating factor 1 (Csf1). Thus, we hypothesized that CSF1 receptor-mediated depletion of myeloid cells using PLX5622 modifies the disease progression and neuropathological phenotype in this mouse model. Intriguingly, sex-balanced analysis of myeloid cell depletion in MBP29-hα-syn mice revealed a two-faced outcome comprising an improved survival rate accompanied by a delayed onset of neurological symptoms in contrast to severely impaired motor functions. Furthermore, PLX5622 reversed gene expression profiles related to myeloid cell activation but reduced gene expression associated with transsynaptic signaling and signal release. While transcriptional changes were accompanied by a reduction of dopaminergic neurons in the SNpc, striatal neuritic density was increased upon myeloid cell depletion in MBP29-hα-syn mice. Together, our findings provide insight into the complex, two-faced role of myeloid cells in the context of MSA emphasizing the importance to carefully balance the beneficial and adverse effects of CSF1R inhibition in different models of neurodegenerative disorders before its clinical translation.

SIGNIFICANCE STATEMENT Myeloid cells have been implicated as detrimental in the disease pathogenesis of multiple system atrophy. However, long-term CSF1R-dependent depletion of these cells in a mouse model of multiple system atrophy demonstrates a two-faced effect involving an improved survival associated with a delayed onset of disease and reduced inflammation which was contrasted by severely impaired motor functions, synaptic signaling, and neuronal circuitries. Thus, this study unraveled a complex role of myeloid cells in multiple system atrophy, which indicates important functions beyond the previously described disease-associated, destructive phenotype and emphasized the need of further investigation to carefully and individually fine-tune immunologic processes in different neurodegenerative diseases.

  • Received March 22, 2022.
  • Revision received August 3, 2022.
  • Accepted August 15, 2022.